Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

DOM-AI

From Wikipedia, the free encyclopedia

Pharmaceutical compound
DOM-AI
Clinical data
Other namesDOMAI; 4,7-Dimethoxy-5-methyl-2-aminoindane; 2-Amino-4,7-dimethoxy-5-methylindane
Drug classSerotonergic psychedelic;Hallucinogen
ATC code
  • None
Identifiers
  • 4,7-dimethoxy-5-methyl-2,3-dihydro-1H-inden-2-amine
CAS Number
PubChemCID
ChemSpider
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC12H17NO2
Molar mass207.273 g·mol−1
3D model (JSmol)
  • CC1=CC(=C2CC(CC2=C1OC)N)OC
  • InChI=1S/C12H17NO2/c1-7-4-11(14-2)9-5-8(13)6-10(9)12(7)15-3/h4,8H,5-6,13H2,1-3H3
  • Key:LBSOVXNUJAVVNS-UHFFFAOYSA-N

DOM-AI, also known as4,7-dimethoxy-5-methyl-2-aminoindane, is a putativeserotonergic psychedelic of the2-aminoindane family related toDOM.[1][2][3][4] It is acyclized phenethylamine and the cyclized 2-aminoindaneanalogue of DOM.[1][2][4]

The drug fully substituted forLSD in rodentdrug discrimination tests, suggesting that it may havehallucinogenic effects in humans.[4] However, DOM-AI was much lesspotent than DOM in these tests, with anED50Tooltip median effective dose of 2.18 mg/kg, which was approximately 1/15th that of DOM.[4] Nonetheless, DOM-AI is still active in showing psychedelic-like effects in animals, in contrast to its analoguesDOM-AT andDOM-CR.[4][5]

DOM-AI was first described in thescientific literature byDavid E. Nichols and colleagues in 1974.[1][6]

Other cyclized analogues of DOM and related psychedelics besides DOM-AI, DOM-AT, and DOM-CR includeDMCPA,TFMBOX,jimscaline,TCB-2,LPH-5, andZC-B.[7][8][2]

See also

[edit]

References

[edit]
  1. ^abcNichols DE, Barfknecht CF, Long JP, Standridge RT, Howell HG, Partyka RA, et al. (February 1974)."Potential psychotomimetics. 2. Rigid analogs of 2,5-dimethoxy-4-methylphenylisopropylamine (DOM, STP)".Journal of Medicinal Chemistry.17 (2):161–166.doi:10.1021/jm00248a004.PMID 4809251.
  2. ^abcNichols DE, Weintraub HJ, Pfister WR, Yim GK (1978)."The use of rigid analogues to probe hallucinogen receptors"(PDF).NIDA Research Monograph (22):70–83.PMID 101889. Archived fromthe original(PDF) on August 5, 2023.
  3. ^Nichols DE (August 1981)."Structure-activity relationships of phenethylamine hallucinogens".Journal of Pharmaceutical Sciences.70 (8):839–849.Bibcode:1981JPhmS..70..839N.doi:10.1002/jps.2600700802.PMID 7031221.
  4. ^abcdeNichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)".Journal of Medicinal Chemistry.33 (2):703–710.doi:10.1021/jm00164a037.PMID 1967651.In addition, a 2-aminoindan (5a) and 2-aminotetralin (5b) congener of the hallucinogenic amphetamine [DOM] were also evaluated. [...] Compounds 5a and 5b did not substitute in MDMA-trained rats, although 5a substituted in LSD-trained rats, but with relatively low potency compared to its open-chain counterpart. [...] The results of the drug discrimination studies in rats are presented in Tables I and II. In the LSD-trained rats, stimulus generalization did not occur with any of the compounds 3a,b, 4a,b or 5b. [...] However, indan 5a gave full substitution, with an ED50 = 2.18 mg/kg, approximately 1/15 the potency of the hallucinogen DOM in this assay.24 Earlier studies of this compound, using disruption of a conditioned-avoidance response, did not produce results suggestive of hallucinogenlike activity.18
  5. ^Glennon RA, Young R, Rangisetty JB (May 2002). "Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline".Pharmacology, Biochemistry, and Behavior.72 (1–2):379–387.doi:10.1016/s0091-3057(01)00768-7.PMID 11900809.
  6. ^Malicky JL, Coutts RT (1 February 1974)."The Synthesis of Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM). II. Some Ring-methoxylated 1-Amino-and 2-Aminoindanes".Canadian Journal of Chemistry.52 (3):381–389.doi:10.1139/v74-061.ISSN 0008-4042.
  7. ^Nichols DE (2018).Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43.doi:10.1007/7854_2017_475.ISBN 978-3-662-55878-2.PMID 28401524.
  8. ^Monte AP (August 1995).Structure-activity relationships of hallucinogens: Design, synthesis, and pharmacological evaluation of a series of conformationally restricted phenethylamines (Ph.D. thesis). Purdue University. Retrieved15 April 2025.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=DOM-AI&oldid=1320844798"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp